Facing the Challenges in Vaccine Upstream Bioprocessing - 24

Facing the Challenges in Vaccine Upstream Bioprocessing * rAAV Production in Suspension CAP GT® Cells in BioBLU® 3c and 10c Single-Use Vessels

experiments can be conducted in parallel, costs
for media are kept low, and not much lab space
is required to operate small-scale bioreactors. But
in the course of biopharmaceutical development
more material is needed for characterization, trial
runs, and finally for commercialization. To maintain
product yield and product quality while scaling up,
bioprocess engineers usually aim to keep one or
more process parameters constant across scales.
Stirred-tank bioreactors with similar vessel geometries and capabilities across scales simplify
scale-up, as they allow keeping critical parameters
constant. Parameters to describe the vessel geometry include impeller diameter, vessel diameter,
liquid height and ratios thereof. Key engineering
parameters related to scale-up include the tip
speed, mixing time, volumetric mass transfer coefficient (kLa), and the power input/volume ratio
(P/V). It depends on the process, which of these
parameters is most important. Cevec Pharmaceuticals uses a unique human cell-based expression
system (CAP Technology) in two product portfolios. One is the glyco-optimized CAP Go® cell line
for tailor-made production of N- or O-glycosylated
24

| GENengnews.com

Figure 1. BioFlo 320 bioprocess control station (left) and the BioBLU c Single-Use
Vessels (right) used in this study.



http://www.GENengnews.com

Facing the Challenges in Vaccine Upstream Bioprocessing

Table of Contents for the Digital Edition of Facing the Challenges in Vaccine Upstream Bioprocessing

Contents
Facing the Challenges in Vaccine Upstream Bioprocessing - 1
Facing the Challenges in Vaccine Upstream Bioprocessing - 2
Facing the Challenges in Vaccine Upstream Bioprocessing - 3
Facing the Challenges in Vaccine Upstream Bioprocessing - Contents
Facing the Challenges in Vaccine Upstream Bioprocessing - 5
Facing the Challenges in Vaccine Upstream Bioprocessing - 6
Facing the Challenges in Vaccine Upstream Bioprocessing - 7
Facing the Challenges in Vaccine Upstream Bioprocessing - 8
Facing the Challenges in Vaccine Upstream Bioprocessing - 9
Facing the Challenges in Vaccine Upstream Bioprocessing - 10
Facing the Challenges in Vaccine Upstream Bioprocessing - 11
Facing the Challenges in Vaccine Upstream Bioprocessing - 12
Facing the Challenges in Vaccine Upstream Bioprocessing - 13
Facing the Challenges in Vaccine Upstream Bioprocessing - 14
Facing the Challenges in Vaccine Upstream Bioprocessing - 15
Facing the Challenges in Vaccine Upstream Bioprocessing - 16
Facing the Challenges in Vaccine Upstream Bioprocessing - 17
Facing the Challenges in Vaccine Upstream Bioprocessing - 18
Facing the Challenges in Vaccine Upstream Bioprocessing - 19
Facing the Challenges in Vaccine Upstream Bioprocessing - 20
Facing the Challenges in Vaccine Upstream Bioprocessing - 21
Facing the Challenges in Vaccine Upstream Bioprocessing - 22
Facing the Challenges in Vaccine Upstream Bioprocessing - 23
Facing the Challenges in Vaccine Upstream Bioprocessing - 24
Facing the Challenges in Vaccine Upstream Bioprocessing - 25
Facing the Challenges in Vaccine Upstream Bioprocessing - 26
Facing the Challenges in Vaccine Upstream Bioprocessing - 27
Facing the Challenges in Vaccine Upstream Bioprocessing - 28
Facing the Challenges in Vaccine Upstream Bioprocessing - 29
Facing the Challenges in Vaccine Upstream Bioprocessing - 30
Facing the Challenges in Vaccine Upstream Bioprocessing - 31
Facing the Challenges in Vaccine Upstream Bioprocessing - 32
Facing the Challenges in Vaccine Upstream Bioprocessing - 33
Facing the Challenges in Vaccine Upstream Bioprocessing - 34
Facing the Challenges in Vaccine Upstream Bioprocessing - 35
https://www.nxtbookmedia.com